Feasibility of using pemetrexed as a salvage regimen in heavily pre-treated patients with ovarian cancer: A retrospective review

被引：1
|
作者：
Dottino, Peter [1 ]
Dashkoff, Matthew [1 ]
Beddoe, Ann Marie [1 ]
机构：
[1] Icahn Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA
来源：
INDIAN JOURNAL OF CANCER | 2020年 / 57卷 / 04期
关键词：
SURVIVAL;
D O I：
10.4103/ijc.IJC_284_19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：491 / 493
页数：3
相关论文
共 50 条
  • [1] Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study
    Asmane, Irene
    Kurtz, Jean-Emmanuel
    Bajard, Agathe
    Guastalla, Jean-Paul
    Meeus, Pierre
    Tredan, Olivier
    Galy, Intidhar Labidi
    Moullet, Isabelle
    Ardisson, Philippe
    Vincent, Lionel
    Coeffic, David
    Dufresne, Armelle
    Bergerat, Jean-Pierre
    Ray-Coquard, Isabelle
    BULLETIN DU CANCER, 2011, 98 (09) : E80 - E89
  • [2] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Bartsch, Rupert
    Wenzel, Catharina
    Gampenrieder, Simon P.
    Pluschnig, Ursula
    Altorjai, Gabriela
    Rudas, Margaretha
    Mader, Robert M.
    Dubsky, Peter
    Rottenfusser, Andrea
    Gnant, Michael
    Zielinski, Christoph C.
    Steger, Guenther G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 903 - 910
  • [3] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Rupert Bartsch
    Catharina Wenzel
    Simon P. Gampenrieder
    Ursula Pluschnig
    Gabriela Altorjai
    Margaretha Rudas
    Robert M. Mader
    Peter Dubsky
    Andrea Rottenfusser
    Michael Gnant
    Christoph C. Zielinski
    Guenther G. Steger
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 903 - 910
  • [4] Weekly topotecan as a salvage therapy in heavily pre-treated patients with recurrent platinum-resistant epithelial ovarian cancer
    Marinaccio, M.
    De Marino, E.
    Mele, E.
    Catacchio, R.
    Meo, D.
    Iezzoni, C.
    Conversano, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] FEASIBILITY STUDY OF A GEMCITABINE COMBINED REGIMEN IN HEAVILY PRE-TREATED PATIENTS WITH NON-HODGKIN LYMPHOMAS
    Kato, Harumi
    Yamamoto, Kazuhito
    Kagami, Yoshitoyo
    Murakami, Satsuki
    Hirano, Daiki
    Taji, Hirofumi
    Morishima, Yasuo
    Kinoshita, Tomohiro
    ANNALS OF ONCOLOGY, 2014, 25
  • [6] Bevacizumab in heavily pre-treated ovarian cancer patients and the predictive value of serum VEGF
    Smerdel, M.
    Steffensen, K. D.
    Waldstrom, M.
    Brandslund, I.
    Jakobsen, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 451 - 451
  • [7] Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
    José Miguel Jurado García
    Alfonso Sánchez
    Bella Pajares
    Elisabeth Pérez
    Lorenzo Alonso
    Emilio Alba
    Clinical and Translational Oncology, 2008, 10
  • [8] Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
    Jurado Garcia, Jose Miguel
    Sanchez, Alfonso
    Pajares, Bella
    Perez, Elisabeth
    Alonso, Lorenzo
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (09): : 583 - 586
  • [9] Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
    José Miguel Jurado
    Alfonso Sánchez
    Bella Pajares
    Elisabeth Pérez
    Lorenzo Alonso
    Emilio Alba
    Clinical and Translational Oncology, 2008, 10 (11) : 772 - 772
  • [10] Bevacizumab toxicity in heavily pre-treated recurrent epithelial ovarian cancer
    Martin, I.
    Urban, R.
    Goff, B.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 197 - 197
12345